MEGAN HERBER

Medication safety; pharmacy regulation and licensure; drug supply chain security; prescription drug monitoring programs; and health provider workforce (HR 929 Dr. Lorna Breen Health Care Provider Protection Reauthorization Act). Combatting the opioid epidemic including ensuring MOUD access, DEA telehealth rules, and H.R. 2483 SUPPORT for Patients and Communities Reauthorization Act; CMS DMEPOS accreditation program.

Medication safety; pharmacy regulation and licensure; drug supply chain security; prescription drug monitoring programs; Combatting the opioid epidemic including ensuring MOUD access, DEA telehealth rules; CMS DMEPOS accreditation program; S. 3794 SAFE Drugs Act.

Support BRAIN Initiative and VA Neurology Centers of Excellence appropriations; Support H.R. 9693 Patients First Act; Support H.R. 5509/S. 2903 SAFE STEP Act; Support H.R. 3514/S.1816 Seniors Timely Access to Care Act; Support H.R. 929/S. 266 Dr. Lorna Breen Health Care Provider Protection Reauthorization Act; Support H.R. 7961 H-1B Visas for Physicians and the Healthcare Workforce Act; Oppose H.R. 139 Sunshine Protection Act.

NIH, CDC, FDA, Medicaid and DOD issues and funding relating to muscular dystrophy research and programs.

Medical research, FDA regulatory, Public health, Medicaid

Federal immunization and vaccine policies including changes to the ACIP and impact on the PI community; Federal funding for primary immunodeficiency research; Federal newborn screening policies; H.R. 8425, Strengthening the Vaccines for Children Program Act.

H.R. 8528 PI Post-Acute Access Act and policies to address access to immunoglobulin during Medicare-covered Skilled Nursing Facility admissions.

FY 27 community project funding.

FY 26 and FY 26 budget and funding for the National Institutes of Health; structural issues of the NIH (Agency for Healthcare Research and Quality (AHRQ) and other HHS agencies); grant terminations. Funding for the Childrens Hospital Graduate Medical Education (CHGME) program; Food and Drug Administration and policies pertaining to development of therapies to treat children with rare diseases; Proposed OMB Regulation for Federal Financial Assistance; PDUFA VIII policies; Policies to improve cancer screening recommendations.

NIH, CDC, FDA, Medicaid and DOD issues and funding relating to muscular dystrophy research and programs.

Medical research, FDA regulatory, Public health, Medicaid

RISE Committee negotiated rulemaking on OBBBA graduate student loan changes, support for the inclusion of clinical psychology as a professional degree program; FY27 Congressionally Directed Spending application.

RISE Committee negotiated rulemaking on OBBBA graduate student loan changes, support for the inclusion of clinical psychology as a professional degree program; FY27 Congressionally Directed Spending application.

Skinny Labels, Big Savings Act (S 43). Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals (S 1096, HR 1843). Implementation of Inflation Reduction Act pricing proposal. Oversight and reform efforts affecting pharmacy benefit managers. Patent reform (S 1095, S 1097). Proposals related to drug shortages. Proposals related to pharmaceutical tariffs; Proposals related to drug pricing reform; Schizophrenia treatment awareness.

Skinny Labels, Big Savings Act (S 43). Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals (S 1096, HR 1843). Implementation of Inflation Reduction Act pricing proposal. Oversight and reform efforts affecting pharmacy benefit managers. Patent reform (S 1095, S 1097). Proposals related to drug shortages. Proposals related to pharmaceutical tariffs; Proposals related to drug pricing reform; Schizophrenia treatment awareness.

Access to Genetic Counselor Services Act, H.R. 6280/S. 3607; NIH funding; newborn screening; regulation of genetic testing and genetic counseling; Medicaid coverage; telehealth access; Reducing Hereditary Cancer Act.

Medication safety; pharmacy regulation and licensure; drug supply chain security; prescription drug monitoring programs; and health provider workforce (HR 929 Dr. Lorna Breen Health Care Provider Protection Reauthorization Act). Combatting the opioid epidemic including ensuring MOUD access, DEA telehealth rules, and H.R. 2483 SUPPORT for Patients and Communities Reauthorization Act; CMS DMEPOS accreditation program.

Medication safety; pharmacy regulation and licensure; drug supply chain security; prescription drug monitoring programs; Combatting the opioid epidemic including ensuring MOUD access, DEA telehealth rules; CMS DMEPOS accreditation program; S. 3794 SAFE Drugs Act.

Congressionally Directed Spending request; Federal funding for employment training and other services.

BRAIN Initiative and VA Neurology Centers of Excellence appropriations

Accelerating Kids' Access to Care Act (S. 752/H.R. 1509) and the Consolidated Appropriations Act; Implementation of Act via rulemaking process.

FY 26 and FY 26 budget and funding for the National Institutes of Health; structural issues of the NIH (Agency for Healthcare Research and Quality (AHRQ) and other HHS agencies); grant terminations. Funding for the Childrens Hospital Graduate Medical Education (CHGME) program; Food and Drug Administration and policies pertaining to development of therapies to treat children with rare diseases; Proposed OMB Regulation for Federal Financial Assistance.

Legislation to address access to immunoglobulin during Medicare-covered Skilled Nursing Facility admissions.

Federal immunization and vaccine policies including changes to the ACIP and impact on the PI community; Federal funding for primary immunodeficiency research; Federal newborn screening policies.

Legislation to address access to immunoglobulin during Medicare-covered Skilled Nursing Facility admissions.

Federal immunization and vaccine policies including changes to the ACIP and impact on the PI community; federal funding for primary immunodeficiency research; Reporting of NIH spending on primary immunodeficiency disease research; federal newborn screening policies.

FY 26 and FY 26 budget and funding for the National Institutes of Health; structural issues of the NIH (Agency for Healthcare Research and Quality (AHRQ) and other HHS agencies); grant terminations. Funding for the Childrens Hospital Graduate Medical Education (CHGME) program; Food and Drug Administration and policies pertaining to development of therapies to treat children with rare diseases.

Accelerating Kids' Access to Care Act (S. 752/H.R. 1509) and the Consolidated Appropriations Act; Implementation of Act via rulemaking process.

FY 27 community project funding.

NIH, CDC, FDA, Medicaid and DOD issues and funding relating to muscular dystrophy research and programs.

Medical research, FDA regulatory, Public health, Medicaid

Access to Genetic Counselor Services Act, H.R. 6280/S. 3607; NIH funding; newborn screening; regulation of genetic testing and genetic counseling; Medicaid coverage; telehealth access; Reducing Hereditary Cancer Act.

RISE Committee negotiated rulemaking on OBBBA graduate student loan changes, support for the inclusion of clinical psychology as a professional degree program; FY27 Congressionally Directed Spending application.

RISE Committee negotiated rulemaking on OBBBA graduate student loan changes, support for the inclusion of clinical psychology as a professional degree program; FY27 Congressionally Directed Spending application.

Skinny Labels, Big Savings Act (S 43). Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals (S 1096, HR 1843). Implementation of Inflation Reduction Act pricing proposal. Oversight and reform efforts affecting pharmacy benefit managers. Patent reform (S 1095, S 1097). Proposals related to drug shortages. Proposals related to pharmaceutical tariffs; Proposals related to drug pricing reform.

Skinny Labels, Big Savings Act (S 43). Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals (S 1096, HR 1843). Implementation of Inflation Reduction Act pricing proposal. Oversight and reform efforts affecting pharmacy benefit managers. Patent reform (S 1095, S 1097). Proposals related to drug shortages. Proposals related to pharmaceutical tariffs; Proposals related to drug pricing reform.

Congressionally Directed Spending request; Federal funding for employment training and other services.

Medication safety; pharmacy regulation and licensure; drug supply chain security; prescription drug monitoring programs; and health provider workforce (HR 929 Dr. Lorna Breen Health Care Provider Protection Reauthorization Act). Combatting the opioid epidemic including ensuring MOUD access, DEA telehealth rules, and H.R. 2483 SUPPORT for Patients and Communities Reauthorization Act; CMS DMEPOS accreditation program.

Medication safety; pharmacy regulation and licensure; drug supply chain security; prescription drug monitoring programs; Combatting the opioid epidemic including ensuring MOUD access, DEA telehealth rules; CMS DMEPOS accreditation program; S. 3794 SAFE Drugs Act.

Support for telehealth (HR 1650/S 763), CONNECT for Health Act (HR 4206/S 1261), Telemental Health Care Access Act (HR 3432/S3651; Telehealth Modernization Act (HR 508/S 2709).

Support for telehealth (HR 1650/S 763), CONNECT for Health Act (HR 4206/S 1261), Telemental Health Care Access Act (HR 3432/S3651; Telehealth Modernization Act (HR 508/S 2709).

BRAIN Initiative and VA Neurology Centers of Excellence appropriations

Appropriations and legislative advocacy

NIH, CDC, FDA, Medicaid and DOD issues and funding relating to muscular dystrophy research and programs.

Medical research, FDA regulatory, Public health, Medicaid

RISE Committee negotiated rulemaking on OBBBA graduate student loan changes, support for the inclusion of clinical psychology as a professional degree program.

Support health care price transparency legislation (S. 2355 Patients Deserve Price Tags Act and S. 2420/HR 4710 No Surprises Act Enforcement Act); Support PBM transparency legislation.

Support health care price transparency legislation (S. 2355 Patients Deserve Price Tags Act and S. 2420/HR 4710 No Surprises Act Enforcement Act); Support PBM transparency legislation.

Skinny Labels, Big Savings Act (S 43). Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals (S 1096, HR 1843). Implementation of Inflation Reduction Act pricing proposal. Oversight and reform efforts affecting pharmacy benefit managers. Patent reform (S 1095, S 1097). Proposals related to drug shortages. Proposals related to pharmaceutical tariffs; Proposals related to drug pricing reform.

Skinny Labels, Big Savings Act (S 43). Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals (S 1096, HR 1843). Implementation of Inflation Reduction Act pricing proposal. Oversight and reform efforts affecting pharmacy benefit managers. Patent reform (S 1095, S 1097). Proposals related to drug shortages. Proposals related to pharmaceutical tariffs; Proposals related to drug pricing reform.

Access to Genetic Counselor Services Act, H.R. 6280; NIH funding; newborn screening; regulation of genetic testing and genetic counseling; Medicaid coverage; telehealth access; Reducing Hereditary Cancer Act.

Medication safety; pharmacy regulation and licensure; drug supply chain security; prescription drug monitoring programs; and health provider workforce (HR 929 Dr. Lorna Breen Health Care Provider Protection Reauthorization Act). Combatting the opioid epidemic including ensuring MOUD access, DEA telehealth rules, and H.R. 2483 SUPPORT for Patients and Communities Reauthorization Act; CMS DMEPOS accreditation program.

Medication safety; pharmacy regulation and licensure; drug supply chain security; prescription drug monitoring programs; and health provider workforce (HR 929 Dr. Lorna Breen Health Care Provider Protection Reauthorization Act). Combatting the opioid epidemic including ensuring MOUD access, DEA telehealth rules, and H.R. 2483 SUPPORT for Patients and Communities Reauthorization Act; CMS DMEPOS accreditation program.

Congressionally Directed Spending request; Federal funding for employment training and other services.

Support for telehealth (HR 1650/S 763), CONNECT for Health Act (HR 4206/S 1261), Telemental Health Care Access Act (HR 3432/S3651; Telehealth Modernization Act (HR 508/S 2709).

Support for telehealth (HR 1650/S 763), CONNECT for Health Act (HR 4206/S 1261), Telemental Health Care Access Act (HR 3432/S3651; Telehealth Modernization Act (HR 508/S 2709).

Federal immunization and vaccine policies including changes to the ACIP and impact on the PI community; federal funding for primary immunodeficiency research; Reporting of NIH spending on primary immunodeficiency disease research; federal newborn screening policies.

Legislation to address access to immunoglobulin during Medicare-covered Skilled Nursing Facility admissions; Medicaid and budget reconciliation; H.R. 1/One Big Beautiful Bill.

FY 26 budget and funding for the National Institutes of Health; structural issues of the NIH; grant terminations. Funding for the Childrens Hospital Graduate Medical Education (CHGME) program.

Accelerating Kids' Access to Care Act (H.R. 1509/S. 752) and related out-of-state Medicaid issues; Medicaid funding and policy issues as part of H.R. 1, budget reconciliation/One Big, Beautiful Bill Act and implementation of the law.

Federal loan and grant support for higher education (GRAD PLUS loans, TRIO, etc); Mental and behavioral health workforce issues

Federal loan and grant support for higher education (GRAD PLUS loans, TRIO, etc); Mental and behavioral health workforce issues

NIH, CDC, FDA, Medicaid and DOD issues and funding relating to muscular dystrophy research and programs.

Medical research, FDA regulatory, Public health, Medicaid

Medical research, FDA regulatory, Public health, Medicaid

Support health care price transparency legislation (S. 2355 Patients Deserve Price Tags Act and S. 2420/HR 4710 No Surprises Act Enforcement Act); Support PBM transparency legislation.

Support health care price transparency legislation (S. 2355 Patients Deserve Price Tags Act and S. 2420/HR 4710 No Surprises Act Enforcement Act); Support PBM transparency legislation.

Skinny Labels, Big Savings Act (S 43). Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals (S 1096, HR 1843). Implementation of Inflation Reduction Act pricing proposal. Oversight and reform efforts affecting pharmacy benefit managers. Patent reform (S 1095, S 1097). Proposals related to drug shortages. Proposals related to pharmaceutical tariffs; Proposals related to drug pricing reform.

Skinny Labels, Big Savings Act (S 43). Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals (S 1096, HR 1843). Implementation of Inflation Reduction Act pricing proposal. Oversight and reform efforts affecting pharmacy benefit managers. Patent reform (S 1095, S 1097). Proposals related to drug shortages. Proposals related to pharmaceutical tariffs; Proposals related to drug pricing reform.

Access to Genetic Counselor Services Act; NIH funding; newborn screening; regulation of genetic testing and genetic counseling; Medicaid coverage; telehealth access; Reducing Hereditary Cancer Act.

Medication safety; pharmacy regulation and licensure; drug supply chain security; prescription drug monitoring programs; and health provider workforce (HR 929 Dr. Lorna Breen Health Care Provider Protection Reauthorization Act). Combatting the opioid epidemic including ensuring MOUD access, DEA telehealth rules, and H.R. 2483 SUPPORT for Patients and Communities Reauthorization Act.

Medication safety; pharmacy regulation and licensure; drug supply chain security; prescription drug monitoring programs; and health provider workforce (HR 929 Dr. Lorna Breen Health Care Provider Protection Reauthorization Act). Combatting the opioid epidemic including ensuring MOUD access, DEA telehealth rules, and H.R. 2483 SUPPORT for Patients and Communities Reauthorization Act.

Congressionally Directed Spending request; Federal funding for employment training and other services.

Support for telehealth (HR 1650/S 763), CONNECT for Health Act (HR 4206/S 1261), Telemental Health Care Access Act (HR 3432/S3651; Telehealth Modernization Act (HR 508/S 2709).

Support for telehealth (HR 1650/S 763), CONNECT for Health Act (HR 4206/S 1261), Telemental Health Care Access Act (HR 3432/S3651; Telehealth Modernization Act (HR 508/S 2709).

Federal immunization and vaccine policies including changes to the ACIP and impact on the PI community; federal funding for primary immunodeficiency research; Reporting of NIH spending on primary immunodeficiency disease research; federal newborn screening policies.

Legislation to address access to immunoglobulin during Medicare-covered Skilled Nursing Facility admissions; Medicaid and budget reconciliation; H.R. 1/One Big Beautiful Bill.

FY 26 primary immunodeficiency research and public health funding.

FY 26 budget and funding for the National Institutes of Health; structural issues of the NIH; grant terminations. Funding for the Childrens Hospital Graduate Medical Education (CHGME) program.

Accelerating Kids' Access to Care Act (H.R. 1509/S. 752) and related out-of-state Medicaid issues; Medicaid funding and policy issues as part of H.R. 1, budget reconciliation/One Big, Beautiful Bill Act and implementation of the law.

Congressionally Directed Spending request; Federal funding for employment training and other services.

Congressionally Directed Spending request; Federal funding for employment training and other services.

Congressionally Directed Spending request; Federal funding for employment training and other services.

Access to Genetic Counselor Services Act; NIH funding; newborn screening; regulation of genetic testing and genetic counseling; Medicaid coverage; telehealth access; Reducing Hereditary Cancer Act.

NIH, CDC, FDA, and DOD issues and funding relating to muscular dystrophy research and programs.

Support health care price transparency and PBM reform legislation.

Support health care price transparency and PBM reform legislation.

Skinny Labels, Big Savings Act (S 43). Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals (S 1096, HR 1843). Implementation of Inflation Reduction Act pricing proposal. Oversight and reform efforts affecting pharmacy benefit managers. Patent reform (S 1095, S 1097). Proposals related to drug shortages. Proposals related to pharmaceutical tariffs.

Skinny Labels, Big Savings Act (S 43). Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals (S 1096, HR 1843). Implementation of Inflation Reduction Act pricing proposal. Oversight and reform efforts affecting pharmacy benefit managers. Patent reform (S 1095, S 1097). Proposals related to drug shortages. Proposals related to pharmaceutical tariffs.

Congressionally Directed Spending request; Federal funding for employment training and other services.

Medication safety; pharmacy regulation and licensure; drug supply chain security; prescription drug monitoring programs; and health provider workforce (HR 929 Dr. Lorna Breen Health Care Provider Protection Reauthorization Act). Combatting the opioid epidemic including ensuring MOUD access, DEA telehealth rules, and H.R. 2483 SUPPORT for Patients and Communities Reauthorization Act.

Medication safety; pharmacy regulation and licensure; drug supply chain security; prescription drug monitoring programs; and health provider workforce (HR 929 Dr. Lorna Breen Health Care Provider Protection Reauthorization Act). Combatting the opioid epidemic including ensuring MOUD access, DEA telehealth rules, and H.R. 2483 SUPPORT for Patients and Communities Reauthorization Act.

Support continuation of first-dollar coverage for telehealth (HR 1650/S 763), CONNECT for Health Act (S 1261), Telemental Health Care Access Act.

Support continuation of first-dollar coverage for telehealth (HR 1650/S 763), CONNECT for Health Act (S 1261), Telemental Health Care Access Act.

Federal immunization and vaccine policies including changes to the ACIP and impact on the PI community; federal funding for primary immunodeficiency research; Reporting of NIH spending on primary immunodeficiency disease research; federal newborn screening policies.

Legislation to address access to immunoglobulin during Medicare-covered Skilled Nursing Facility admissions; Medicaid and budget reconciliation; H.R. 1/One Big Beautiful Bill.

FY 26 primary immunodeficiency research and public health funding.

FY 26 budget and funding for the National Institutes of Health; structural issues of the NIH; grant terminations. Funding for the Childrens Hospital Graduate Medical Education (CHGME) program.

Accelerating Kids' Access to Care Act (H.R. 1509/S. 752) and related out-of-state Medicaid issues; Medicaid funding and policy issues as part of H.R. 1, budget reconciliation/One Big, Beautiful Bill Act.

Funding for biomedical research and changes to NIH F&A rate calculations. Make America Healthy Again commission and related policy issues pertaining to the transition.

Accelerating Kids' Access to Care Act (H.R. 1509/S. 752) and related out-of-state Medicaid issues; Medicaid funding and budget reconciliation.

Access to Genetic Counselor Services Act; NIH funding; newborn screening; regulation of genetic testing and genetic counseling; Medicaid coverage; telehealth access; Reducing Hereditary Cancer Act.

NIH, CDC, FDA, and DOD issues and funding relating to muscular dystrophy research and programs.

Skinny Labels, Big Savings Act (S 43). Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals (S 1096, HR 1843). Implementation of Inflation Reduction Act pricing proposal. Oversight and reform efforts affecting pharmacy benefit managers. Patent reform (S 1095, S 1097). Proposals related to drug shortages. Proposals related to pharmaceutical tariffs.

Skinny Labels, Big Savings Act (S 43). Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals (S 1096, HR 1843). Implementation of Inflation Reduction Act pricing proposal. Oversight and reform efforts affecting pharmacy benefit managers. Patent reform (S 1095, S 1097). Proposals related to drug shortages. Proposals related to pharmaceutical tariffs.

Support health care price transparency and PBM reform legislation.

Support health care price transparency and PBM reform legislation.

Medication safety; pharmacy regulation and licensure; drug supply chain security; prescription drug monitoring programs; and health provider workforce (HR 929 Dr. Lorna Breen Health Care Provider Protection Reauthorization Act). Combatting the opioid epidemic including ensuring MOUD access, DEA telehealth rules, and H.R. 2483 SUPPORT for Patients and Communities Reauthorization Act.

Medication safety; pharmacy regulation and licensure; drug supply chain security; prescription drug monitoring programs; and health provider workforce (HR 929 Dr. Lorna Breen Health Care Provider Protection Reauthorization Act). Combatting the opioid epidemic including ensuring MOUD access, DEA telehealth rules, and H.R. 2483 SUPPORT for Patients and Communities Reauthorization Act.

Support continuation of first-dollar coverage for telehealth (HR 1650/S 763), continuation of telehealth ERISA exemption, CONNECT for Health Act (S 1261), Telemental Health Care Access Act.

Support continuation of first-dollar coverage for telehealth (HR 1650/S 763), continuation of telehealth ERISA exemption, CONNECT for Health Act (S 1261), Telemental Health Care Access Act.

Congressionally Directed Spending request; Federal funding for employment training and other services.

Federal immunization and vaccine policy issues impacting the immunocompromised community; federal support for primary immunodeficiency research.

Legislation to address access to immunoglobulin during Medicare-covered Skilled Nursing Facility admissions; Medicaid and budget reconciliation.

FY 26 primary immunodeficiency research and public health funding.

Funding for biomedical research and changes to NIH F&A rate calculations. Make America Healthy Again commission and related policy issues pertaining to the transition.

Accelerating Kids' Access to Care Act (H.R. 1509/S. 752) and related out-of-state Medicaid issues; Medicaid funding and budget reconciliation.

NIH, CDC, FDA, and DOD issues and funding relating to muscular dystrophy research and programs.

HR 5378 Lower Costs, More Transparency, S 3548 Health Care Prices Revealed and Information to Consumers Explained (PRICE) Transparency Act, and HR 9572 Enhanced Enforcement of Health Coverage Act.

HR 5378 Lower Costs, More Transparency, S 3548 Health Care Prices Revealed and Information to Consumers Explained (PRICE) Transparency Act, and HR 9572 Enhanced Enforcement of Health Coverage Act.

Changes to Hatch-Waxman's 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals. Implementation of the Inflation Reduction Act. Drug pricing proposals. Oversight and reform efforts affecting pharmacy benefit managers, including Pharmacy Benefit Manager Transparency Act (S. 127), Prescription Pricing for the People Act (S. 113), and Drug Price Transparency in Medicaid Act of 2023 (H.R. 1613), and Lower Costs, More Transparency Act (H.R. 5378); Patent reform, including the Preserve Access to Affordable Generics and Biosimilars Act (S. 142), Affordable Prescriptions for Patients Act (S. 150); Block, Report, and Suspend Suspicious Shipments Act (H.R. 501); Proposal related to drug shortages.

Changes to Hatch-Waxman's 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals. Implementation of the Inflation Reduction Act. Drug pricing proposals. Oversight and reform efforts affecting pharmacy benefit managers, including Pharmacy Benefit Manager Transparency Act (S. 127), Prescription Pricing for the People Act (S. 113), and Drug Price Transparency in Medicaid Act of 2023 (H.R. 1613), and Lower Costs, More Transparency Act (H.R. 5378); Patent reform, including the Preserve Access to Affordable Generics and Biosimilars Act (S. 142), Affordable Prescriptions for Patients Act (S. 150); Block, Report, and Suspend Suspicious Shipments Act (H.R. 501); Proposal related to drug shortages.

Medication safety; pharmacy regulation and licensure, drug supply chain security and combatting the opioid epidemic including ensuring MOUD access; Prescription drug monitoring programs; HR 501 Block, Report, and Suspend Suspicious Shipments Act; Ryan Haight Act/DEA rule on telehealth; HR 4531/S 2433 SUPPORT for Patients and Communities Reauthorization Act; H.R. 7513/S. 3679 Dr. Loma Breen Health Care Provider Protection Reauthorization Act; H.R. 9886/S. 5271 BUPE for Recovery Act and H.R. 5526 Seniors Access to Critical Medications Act.

Medication safety; pharmacy regulation and licensure, drug supply chain security and combatting the opioid epidemic including ensuring MOUD access; Prescription drug monitoring programs; HR 501 Block, Report, and Suspend Suspicious Shipments Act; Ryan Haight Act/DEA rule on telehealth; HR 4531/S 2433 SUPPORT for Patients and Communities Reauthorization Act; H.R. 7513/S. 3679 Dr. Loma Breen Health Care Provider Protection Reauthorization Act; H.R. 7513/S. 3679 Dr. Loma Breen Health Care Provider Protection Reauthorization Act; H.R. 9886/S.5271 BUPE for Recovery Act and H.R. 5526 Seniors' Access to Critical Medications Act.

Continuation of first-dollar coverage for telehealth H.R. 1843, S. 1001 - Telehealth Expansion Act; Telehealth ERISA exemption H.R. 824 Telehealth Benefit Expansion for Workers Act; CONNECT for Health Act; Telemental Health Care Access Act; health care data transparency; telehealth in Medicare Advantage; streamlining Medical provider enrollment; S 3430 Better Mental Health care, Lower-Cost Drugs, and Extenders Act, HR 5378 Lower Cost, More Transparency, S 2548 Health Care Prices Revealed and Information to Consumers Explained (PRICE) Transparency Act, S 3059 Requiring Enhanced & Accurate Lists of (REAL) Health Providers Act.

Continuation of first-dollar coverage for telehealth H.R. 1843, S. 1001 - Telehealth Expansion Act; Telehealth ERISA exemption H.R. 824 Telehealth Benefit Expansion for Workers Act; CONNECT for Health Act; Telemental Health Care Access Act; health care data transparency; telehealth in Medicare Advantage; streamlining Medical provider enrollment; S 3430 Better Mental Health care, Lower-Cost Drugs, and Extenders Act, HR 5378 Lower Cost, More Transparency, S 2548 Health Care Prices Revealed and Information to Consumers Explained (PRICE) Transparency Act, S 3059 Requiring Enhanced & Accurate Lists of (REAL) Health Providers Act.

H.R.3876/ S.2323 - Access to Genetic Counselor Services Act of 2023

H.R.3876/ S.2323 - Access to Genetic Counselor Services Act of 2023

H.R. 3017, the PI Post Acute Access Act and policies pertaining to access to immunoglobulin (Ig) treatments for Medicare beneficiaries within Skilled Nursing Facilities

Scientific meeting focused on improving diagnostics of PI.

Funding and related issue pertaining to improving diagnostics of PI; H.R. 5397, the Joe Fiandra Access to Home Infusion Act.

Medical research issues pertaining to children's health and the National Institutes of Health; NIH modernization and reform proposals; SUSTAIN 340B Act; Issues pertaining to cell and gene therapies.

H.R. 4758 and S. 2372, the Accelerating Kids' Access to Care Act and issues pertaining to out-of state care for Medicaid and CHIP beneficiaries.

Scientific meeting focused on improving diagnostics of PI.

Funding and related issue pertaining to improving diagnostics of PI; H.R. 5397, the Joe Fiandra Access to Home Infusion Act.

H.R. 3017, the PI Post Acute Access Act and policies pertaining to access to immunoglobulin (Ig) treatments for Medicare beneficiaries within Skilled Nursing Facilities

Congressionally Directed Spending request; Federal funding for employment training and other services

H.R. 3876/S. 2323 Access to Genetic Counselor Services Act.

H.R. 3876/S. 2323 Access to Genetic Counselor Services Act.

NIH, CDC, FDA, and DOD issues and funding relating to muscular dystrophy research and programs.

Congressionally Directed Spending request; Federal funding for employment training and other services

Congressionally Directed Spending request; Federal funding for employment training and other services

Funding and related issue pertaining to improving diagnostics of PI; FDA proposal to regulate Laboratory Developed Tests (LDTs); H.R. 5397, the Joe Fiandra Access to Home Infusion Act.

FY 25 report language pertaining to primary immunodeficiency disease medical research.

H.R. 3017, the PI Post Acute Access Act and policies pertaining to access to immunoglobulin (Ig) treatments for Medicare beneficiaries within Skilled Nursing Facilities

Congressionally Directed Spending request; Federal funding for employment training and other services

Congressionally Directed Spending request; Federal funding for employment training and other services

Medication safety; pharmacy regulation and licensure, drug supply chain security and combatting the opioid epidemic including ensuring MOUD access; Prescription drug monitoring programs; HR 501 Block, Report, and Suspend Suspicious Shipments Act; Ryan Haight Act/DEA rule on telehealth; HR 4531/S 2433 SUPPORT for Patients and Communities Reauthorization Act; H.R. 7513/S. 3679 Dr. Loma Breen Health Care Provider Protection Reauthorization Act; H.R. 7513/S. 3679 Dr. Loma Breen Health Care Provider Protection Reauthorization Act.

Medication safety; pharmacy regulation and licensure, drug supply chain security and combatting the opioid epidemic including ensuring MOUD access; Prescription drug monitoring programs; HR 501 Block, Report, and Suspend Suspicious Shipments Act; Ryan Haight Act/DEA rule on telehealth; HR 4531/S 2433 SUPPORT for Patients and Communities Reauthorization Act; H.R. 7513/S. 3679 Dr. Loma Breen Health Care Provider Protection Reauthorization Act.

Continuation of first-dollar coverage for telehealth H.R. 1843, S. 1001 - Telehealth Expansion Act; Telehealth ERISA exemption H.R. 824 Telehealth Benefit Expansion for Workers Act; CONNECT for Health Act; Telemental Health Care Access Act; health care data transparency; telehealth in Medicare Advantage; streamlining Medical provider enrollment; S 3430 Better Mental Health care, Lower-Cost Drugs, and Extenders Act, HR 5378 Lower Cost, More Transparency, S 2548 Health Care Prices Revealed and Information to Consumers Explained (PRICE) Transparency Act, S 3059 Requiring Enhanced & Accurate Lists of (REAL) Health Providers Act.

Continuation of first-dollar coverage for telehealth H.R. 1843, S. 1001 - Telehealth Expansion Act; Telehealth ERISA exemption H.R. 824 Telehealth Benefit Expansion for Workers Act; CONNECT for Health Act; Telemental Health Care Access Act; health care data transparency; telehealth in Medicare Advantage; streamlining Medical provider enrollment; S 3430 Better Mental Health care, Lower-Cost Drugs, and Extenders Act, HR 5378 Lower Cost, More Transparency, S 2548 Health Care Prices Revealed and Information to Consumers Explained (PRICE) Transparency Act, S 3059 Requiring Enhanced & Accurate Lists of (REAL) Health Providers Act.

Telemedicine legislation including CONNECT for Health Act; Telemental Health Care Access Act; Telehealth Modernization Act, Primary and Virtual Care Affordability Act, Expanding Remote Monitoring Access Act; Preserving Telehealth, Hospital, and Ambulance Access Act (HR 6364); Expanding Remote Monitoring Access Act (HR 53934); Sustainable Cardiopulmonary Rehabilitation (CR) Service in the Home Act (HR 1406).

Telemedicine legislation including CONNECT for Health Act; Telemental Health Care Access Act; TREATS Act; Ryan Haight Act/DEA rulemaking on telemedicine: H.R. 1843, S. 1001 - Telehealth Expansion Act; H.R. 824 Telehealth Benefit Expansion for Workers Act; Telehealth Modernization Act, Primary and Virtual Care Affordability Act, Expanding Remote Monitoring Access Act

Medical research issues pertaining to children's health and the National Institutes of Health; NIH modernization and reform proposals; SUSTAIN 340B Act; Issues pertaining to cell and gene therapies.

FY 2025 community project funding

H.R. 4758 and S. 2372, the Accelerating Kids' Access to Care Act and issues pertaining to out-of state care for Medicaid and CHIP beneficiaries.

Price transparency: H.R. 5378 Lower Costs, More Transparency Act, S.3430 Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023, S. 3548 Health Care Prices Revealed and Information to Consumers Explained (PRICE) Transparency Act

Price transparency: H.R. 5378 Lower Costs, More Transparency Act, S.3430 Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023, S. 3548 Health Care Prices Revealed and Information to Consumers Explained (PRICE) Transparency Act

Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals. Implementation of the Inflation Reduction Act. Drug pricing proposals. Oversight and reform efforts affecting pharmacy benefit managers, including Pharmacy Benefit Manager Transparency Act (S. 127), Prescription Pricing for the People Act (S. 113), and Drug Price Transparency in Medicaid Act of 2023 (H.R. 1613), and Lower Costs, More Transparency Act (H.R. 5378). Patent reform, including the Preserve Access to Affordable Generics and Biosimilars Act (S.142), Affordable Prescriptions for Patients Act (S.150). Block, Report, and Suspend Suspicious Shipments Act (H.R. 501). Proposals related to drug shortages.

Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals. Implementation of the Inflation Reduction Act. Drug pricing proposals. Oversight and reform efforts affecting pharmacy benefit managers, including Pharmacy Benefit Manager Transparency Act (S. 127), Prescription Pricing for the People Act (S. 113), and Drug Price Transparency in Medicaid Act of 2023 (H.R. 1613), and Lower Costs, More Transparency Act (H.R. 5378). Patent reform, including the Preserve Access to Affordable Generics and Biosimilars Act (S.142), Affordable Prescriptions for Patients Act (S.150). Block, Report, and Suspend Suspicious Shipments Act (H.R. 501). Proposals related to drug shortages.